
|Videos|February 18, 2014
The Utility of CAR-Modified T Cells in Myeloid Malignancies
Author(s)Renier J. Brentjens, MD, PhD
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.
Clinical Pearls
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.
- Ideally, CAR-modified T cells should have utility in myeloid malignancies
- Identifying a target for CAR-modified T cells to recognize remains a challenge
- There is always the danger of targeting a protein expressed on normal tissues or stem cells







































